Incyte Corporation (INCY)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Incyte Corporation's Days Sales Outstanding (DSO) for the period spanning December 31, 2019, to December 31, 2024, has not been provided in the data. This key financial ratio is used to measure the average number of days it takes for a company to collect payment after a sale has been made. Without the specific DSO figures, it is challenging to assess Incyte Corporation's efficiency in collecting accounts receivable and managing its cash flow effectively.
However, a high DSO could indicate potential issues in the company's credit policies, collection procedures, or difficulties in obtaining timely payments from customers. Conversely, a low DSO suggests a more efficient accounts receivable management process.
Given the absence of DSO data, it is recommended to monitor this metric going forward to better understand Incyte Corporation's performance in receivables management and its impact on the company's overall financial health.
Peer comparison
Dec 31, 2024